Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Wendys Co — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while Wendys Co trades at $6.48 (market cap $1.23B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 4.1× Wendys Co's market cap, and Wendys Co pays a 4.35% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Wendys Co for 78 Days on average.
| ORKA | WEN | |
|---|---|---|
Market Cap | $5.08B | $1.23B |
Volume | 685,276 | 6,130,931 |
Sector | Health | Consumer Cyclical |
52-Week High | $113.08 | $9.33 |
52-Week Low | $26.19 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $4.21B | $4.96B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wendy's (WEN) trades at $6.35, up 0.63% with a bearish technical outlook. The stock shows attractive valuation metrics with a P/E of 9.62 and P/S of 0.55, but faces fundamental challenges including declining net income margins (5.72% in 2026) and high debt levels. Recent news highlights franchisee bankruptcies and competitive pressures, though the company has beaten earnings expectations for three consecutive quarters. Analyst consensus remains cautious with a $7.58 price target and 64.71% hold rating.
The investment case balances deep value against operational headwinds. While valuation appears compelling, declining profitability, franchisee instability, and intense competition create significant risks. The stock offers a dividend yield but requires successful execution under new leadership to reverse negative trends. Near-term catalysts include Q3 2026 earnings and management's turnaround strategy implementation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
